前列腺癌中的双特异性T细胞参与者 (BiTE) 和增强发育的策略:对BiTE-r未来的希望
Harriet Lampe1, Laura Tam1, Aaron R Hansen1
1Department of Medical Oncology, Division of Cancer Care Services, Princess Alexandra Hospital, Metro South Health Service, Queensland Health, Brisbane, QLD, Australia.
Frontiers in pharmacology
|June 14, 2024
概括
双特异性T细胞参与者 (BiTEs) 对转移性割抗性前列腺癌 (mCRPC) 有前途,但面临挑战. 本综述分析了障碍,并提出了改善mCRPC治疗中BiTE治疗疗效的策略.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 转移性割抗性前列腺癌 (mCRPC) 的有效治疗选择有限,存活率差.
- 双特异性T细胞参与剂 (BiTE) 是新兴的免疫疗法,在其他癌症中取得了成功.
- 前列腺癌特异性的BiTE正在进行mCRPC的临床试验.
研究的目的:
- 分析阻碍mCRPC中BiTE治疗的挑战.
- 研究mCRPC瘤微环境在治疗耐药性的作用.
- 确定克服目前对mCRPC的BiTE治疗局限性的策略.
主要方法:
- 对mCRPC中BTE的临床试验和临床前研究的文献综述.
- 分析与治疗相关的不良事件和抗瘤疗效数据.
- 检查导致抗药抗体生成的因素.
主要成果:
- 在mCRPC中对BiTE的临床试验报告了与治疗相关的重大不良事件.
- 观察到的抗瘤疗效往往是最小的或短暂的.
- 产生了高位的抗药抗体,可能会限制疗效.
结论:
- 目前的BiTE构造和mCRPC瘤微环境对有效治疗提出了重大挑战.
- 需要策略来缓解不良事件,增强抗瘤活性,克服免疫性.
- 进一步的研究至关重要,以优化BTE以改善mCRPC结果.
相关概念视频
Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Vaccines
352
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
352
T Cell Activation and Clonal Selection
701
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
701


